Table 2.
Adjuvant chemotherapy in 143 patients after oncologic resection for pancreatic ductal adenocarcinoma before (period 1) and after (period 2) S3 guideline implementation.
| Period 1 (09/’03–07/’07) (n = 49) | Period 2 (08/’07–08/’14) (n = 94) | p | ||
|---|---|---|---|---|
| Adjuvant chemotherapy | ||||
| Recommended | Yes | n = 42 (86%) | n = 93 (99%) | 0.0024 |
| No | n = 7 (14%) | n = 1 (1%) | ||
| Initiated | Yes | n = 34 (69%) | n = 78 (83%) | 0.0862 |
| No | n = 15 (31%) | n = 16 (17%) | ||
| Completed (6 cycles) | Yes | n = 22 (45%) | n = 49 (52%) | 0.8490 |
| No | n = 12 (24%) | n = 29 (31%) | ||